scholarly journals Proteomics of Primary Uveal Melanoma: Insights into Metastasis and Protein Biomarkers

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3520
Author(s):  
Geeng-Fu Jang ◽  
Jack S. Crabb ◽  
Bo Hu ◽  
Belinda Willard ◽  
Helen Kalirai ◽  
...  
Keyword(s):  
Immune System ◽  
Uveal Melanoma ◽  
Immune Therapy ◽  
Protein Biomarkers ◽  
Prediction Modeling ◽  
Liver Histopathology ◽  
Discriminatory Accuracy ◽  
Melanoma Metastases ◽  
Study Support ◽  
Mascot Search Engine

Uveal melanoma metastases are lethal and remain incurable. A quantitative proteomic analysis of 53 metastasizing and 47 non-metastasizing primary uveal melanoma (pUM) was pursued for insights into UM metastasis and protein biomarkers. The metastatic status of the pUM specimens was defined based on clinical data, survival histories, prognostic analyses, and liver histopathology. LC MS/MS iTRAQ technology, the Mascot search engine, and the UniProt human database were used to identify and quantify pUM proteins relative to the normal choroid excised from UM donor eyes. The determined proteomes of all 100 tumors were very similar, encompassing a total of 3935 pUM proteins. Proteins differentially expressed (DE) between metastasizing and non-metastasizing pUM (n = 402) were employed in bioinformatic analyses that predicted significant differences in the immune system between metastasizing and non-metastasizing pUM. The immune proteins (n = 778) identified in this study support the immune-suppressive nature and low abundance of immune checkpoint regulators in pUM, and suggest CDH1, HLA-DPA1, and several DE immune kinases and phosphatases as possible candidates for immune therapy checkpoint blockade. Prediction modeling identified 32 proteins capable of predicting metastasizing versus non-metastasizing pUM with 93% discriminatory accuracy, supporting the potential for protein-based prognostic methods for detecting UM metastasis.

Uveal Melanoma: Metastases

2019 ◽  
pp. 317-329
Author(s):  
Lucy T. Xu ◽  
Pauline Funchain ◽  
Ahmad A. Tarhini ◽  
Arun D. Singh
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Metastases

Moving Immune Therapy Forward Targeting TME

2020 ◽  
Author(s):  
Kayla F Goliwas ◽  
Jessy S. Deshane ◽  
Craig A Elmets ◽  
Mohammad Athar
Keyword(s):  
Immune System ◽  
Targeted Therapies ◽  
Immune Therapy ◽  
Clinical Trial Design ◽  
Therapeutic Interventions ◽  
Host Immune System ◽  
Host Immune Responses ◽  
Metabolic Plasticity ◽  
Cancer Pathogenesis ◽  
Immune Therapies

The host immune system shapes the fate of tumor progression. Hence, manipulating patients' immune system to activate host immune responses against cancer pathogenesis is a promising strategy to develop effective therapeutic interventions for metastatic and drug resistant cancers. Understanding the dynamic mechanisms within the tumor microenvironment (TME) that contribute to heterogeneity and metabolic plasticity is essential to enhance the patients' responsiveness to immune targeted therapies. Riera-Domingo et. al. describe the immune landscape within the TME, and highlight the significance of metabolic and hypoxic signatures that impact immune function and response to immunotherapy. Current literature in this field confirms that targeting tumor metabolism and the acidic microenvironment commonly associated with tumors may present as viable strategies to modulate the host immune system in favor of developing highly effective immune targeted therapies. However, development of better tools to understand tumor-immune interactions and identify mechanisms driving non-responders, more innovative clinical trial design, and new therapies will need to be identified to move the field forward. Personalized immune therapies incorporating metabolic and microbiome-based gene signatures to influence the therapeutic response and novel methods to generate immunologically "hot" tumors are at the forefront of immunotherapy currently. The combination of these approaches with clinically approved immunotherapies will also be valuable moving forward.

Clonal evolution of uveal melanoma metastases.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21534-e21534
Author(s):  
Jessica Yang ◽  
Heather M. Geiger ◽  
Junfei Zhao ◽  
James C. Chen ◽  
Kanika Arora ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Clonal Evolution ◽  
Melanoma Metastases

scholarly journals Do Extracellular RNAs Provide Insight into Uveal Melanoma Biology?

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5919
Author(s):  
Cristina Barbagallo ◽  
Chiara Bianca Maria Platania ◽  
Filippo Drago ◽  
Davide Barbagallo ◽  
Cinzia Di Pietro ◽  
...  
Keyword(s):  
Immune System ◽  
Uveal Melanoma ◽  
State Of The Art ◽  
Biological Fluids ◽  
Cell Types ◽  
Bodily Fluids ◽  
Biological Meaning ◽  
Ocular Fluids ◽  
Non Coding Rnas ◽  
Insight Into

Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults, showing a high mortality due to metastasis. Although it is considered a rare disease, a growing number of papers have reported altered levels of RNAs (i.e., coding and non-coding RNAs) in cancerous tissues and biological fluids from UM patients. The presence of circulating RNAs, whose dysregulation is associated with UM, paved the way to the possibility of exploiting it for diagnostic and prognostic purposes. However, the biological meaning and the origin of such RNAs in blood and ocular fluids of UM patients remain unexplored. In this review, we report the state of the art of circulating RNAs in UM and debate whether the amount and types of RNAs measured in bodily fluids mirror the RNA alterations from source cancer cells. Based on literature data, extracellular RNAs in UM patients do not represent, with rare exceptions, a snapshot of RNA dysregulations occurring in cancerous tissues, but rather the complex and heterogeneous outcome of a systemic dysfunction, including immune system activity, that modifies the mechanisms of RNA delivery from several cell types.

scholarly journals Staging of uveal melanoma metastases

2012 ◽  
Vol 90 ◽  
pp. 0-0
Author(s):  
T KIVELÄ ◽  
S ESKELIN
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Metastases

scholarly journals Balance and modulation of immunoediting for cancer treatment using synergistic nano-photo-immuno effects

Nanophotonics ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3383-3389
Author(s):  
Ashley R. Hoover ◽  
Kaili Liu ◽  
Wei R. Chen
Keyword(s):  
Immune System ◽  
Cancer Treatment ◽  
Tumor Recurrence ◽  
Tumor Metastasis ◽  
Immune Therapy ◽  
Cancer Diagnostics ◽  
Treatment Modalities ◽  
Host Immune System ◽  
Profound Impact

Abstract Nanotechnology, photonics, and immunotherapy are far-reaching technologies with the potential to revolutionize the field of cancer diagnostics and therapeutics. While each technology has limitations in cancer treatment, they can be synergized to exert profound impact on the balance and modulation of immunoediting in tumor microenvironment (TME) and in the entire host immune system. We provide our perspectives on how nano-photo-immuno interactions can be used as an effective therapy, particularly when combined with other treatment modalities, such as checkpoint immune therapy, chemotherapy, and TME modulation, to provide a long-term, tumor-specific immunity against tumor metastasis and tumor recurrence.

Genetic analyses of uveal melanoma metastases

2012 ◽  
Vol 90 ◽  
pp. 0-0
Author(s):  
S SAULE ◽  
J COUTURIER ◽  
MH STERN ◽  
P MARIANI ◽  
L DESJARDINS ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Genetic Analyses ◽  
Melanoma Metastases
Sign in / Sign up

Export Citation Format

Share Document